ARGENT BIOPHARMA LIMITED (ASX:RGT) - MXC - Nice jump on open, page-36 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by Neil1959 ↑

An older article but maybe clear the fog a little... (a pun)

FINANCIAL REVIEW 2015

Aussie 'pot stock' MGC Pharmaceuticals wins license to grow marijuana

Share via Email

Share on Google Plus

Post on facebook wall

Share on twitter

Post to Linkedin

Share on Reddit

http://www.copyright link/content/dam/images/g/h/5/k/2/j/image.related.afrArticleLead.620x350.ghkgi5.png/1443057878034.jpg
The most recent "pot stock" to trade on the ASX, MGC Pharmaceuticals, has become one of the first local players to be granted a license to grow marijuana for medicinal purposes. AP
http://www.copyright link/content/dam/images/1/4/4/7/0/5/image.imgtype.afrAuthorAvatar.120x120.png/1426319325674.png

Share on twitter

Share on Google Plus

by Jessica Sier
An Australian pharmaceutical company, the most recent "pot stock" to trade on the ASX, has become one of the first local players to be granted a license to grow marijuana for medicinal purposes.
MGC Pharmaceuticals, which is operated out of Israel, will be allowed to grow, process, import and export cannabis from Slovenia, where the government has legalised the practice.
Fellow Australian cannabis producer, AusCann, secured permission to grow and export marijuana on Norfolk Island in May. The difference between the two producers is MGC hopes to produce a product for the cosmetic industry whereas AusCann is targetting pain relief.
MGC Pharmaceuticals recently struck a reverse takeover deal with Erin Resources in the hopes of transforming the languishing gold-explorer into a cannabinoid resin producer.
http://www.copyright link/content/dam/images/g/h/k/v/8/p/image.imgtype.afrArticleInline.620x0.png/1433917117313.jpg
MGC Pharmaceuticals managing director Nativ Segev said receiving the licenses was a key milestone for the company. Supplied
MGC Pharmaceuticals has received two licenses from the Slovenian Government, the Ministry of Agriculture and The Ministry of Hemp and Poppy Control in the region, allowing the business to grow, process and trade Cannabis Sativa L (Hemp) and its products, including Cannabidoil (CBD) resin, in Europe.

CBD has no psychotropic properties, unlike its popular cousin Tetrahydrocannabinol (THC). In the global market, CBD typically sells for between $US50,000 to $US70,000 ($65,000 to $92,000) a kilo.
A key milestone

"Receiving these licenses is a key milestone for MGC," said managing director Nativ Segev. "The ability to both grow and process the Cannabis Sativa (Hemp) on site at the facility in Slovenia sets the business apart from other pure growers in the region and significantly de-risks the businesses path towards near-term commercialisation."
Despite the rush to list medical marijuana companies on the ASX - MGC Pharmaceuticals is the third - the production of cannabis and domestic therapeutic usage is still illegal in Australia, meaning the companies are conducting their actual business anywhere but here.

Perth-based PhytoTech Medical hopes to manufacture vaporisers (smokeless delivery devises) in Israel and service markets across Europe, from cannabis crops in California and Uruguay and was the first "pot stock" to list on the ASX. Phytotech's ASX debut in January saw a doubling of the company's shareprice, giving investors and speculators a great high.
However, the PhytoTech stock took a beating after controversial founder Ross Smith resigned In February following a strange and foul-mouthed rant on social media.
The company is now on track to merge with Canadian grower MMJ Biosciences in a $15.5 million deal.
Fellow ASX-listed Capital Mining is in the process of reinventing its business, acquiring a 24 per cent stake in Canadian company, Broken Coast Cannabis, with an option to acquire up to 50 per cent. The Perth-based mining shell also attempted to acquire 100 per cent of Cannabinoid Extracts Australia from Essential Oils of Tasmania, but the deal fell through.

PM support

Prime Minister Tony Abbott threw his support behind the legislation of cannabis for medical purposes, in letter to talkback radio host Alan Jones last year.
"I have no problem with the medical use of cannabis, just as I have no problem with the medical use of opiates," Mr Abbott wrote in a letter dated August 23 and reported by Fairfax at the time.
"If a drug is needed for a valid medicinal purpose though and is being administered safely there should be no question of its legality. And if a drug that is proven to be safe abroad is needed here it should be available.

"I agree that the regulation of medicines is a thicket of complexity, bureaucracy and corporate and institutional self interest."

Read more: http://www.copyright link/technology/aussie-pot-stock-mgc-pharmaceuticals-wins-license-to-grow-marijuana-20150610-ghkgi5#ixzz4bv4VULBA
Follow us: @FinancialReview on Twitter | financialreview on Facebook

Expand

Dated 2015, relates to Slovenian licence only.

No.	Vol.	Price($)
1	334	51.0¢

No.

Vol.

Price($)

334

51.0¢

Price($)	Vol.	No.
55.0¢	60	1

Price($)

Vol.

No.

55.0¢

No.	Vol.	Price($)
1	334	0.510
1	680	0.470
1	2000	0.460
1	5000	0.450
2	9000	0.445

No.

Vol.

Price($)

334

0.510

680

0.470

2000

0.460

5000

0.450

9000

0.445

Price($)	Vol.	No.
0.550	60	1
0.590	2000	1
0.620	1414	1
0.700	1368	1
0.740	350	1

Price($)

Vol.

No.

0.550

0.590

2000

0.620

1414

0.700

1368

0.740

350

(20min delay)
Last 53.0¢		Change 0.180(51.4%)		Mkt cap ! $25.65M

Open	High	Low	Value	Volume
38.0¢	56.0¢	38.0¢	$71.38K	137.5K

MXC - Nice jump on open, page-36

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Iress runs 'hot' for Wealth Within's stock tips

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Failure to report prompts ASX to impose multiple company suspensions

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MXC - Nice jump on open, page-36

Top Stories

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Iress runs 'hot' for Wealth Within's stock tips

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Failure to report prompts ASX to impose multiple company suspensions

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News